This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, D. P. Articles by Adamson, P. C. Search for Related Content PubMed PubMed Citation Articles by Lee, D. P. Articles by Adamson, P. C. Social Bookmarking                            What's this?

Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency

From the Division of Clinical Pharmacology & Therapeutics, The Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA

Address reprint requests to Peter C. Adamson, MD, Division Chief, Clinical Pharmacology and Therapeutics, The Children's Hospital of Philadelphia, 3516 Civic Center Blvd, ARC 916, Philadelphia, PA 19104; e-mail: adamsonp{at}mail.med.upenn.edu

PURPOSE: To determine the efficacy and safety of pediatric phase I oncology trials in the era of dose-intensive chemotherapy and to analyze how efficiently these trials are conducted.

METHODS: Phase I pediatric oncology trials published from 1990 to 2004 and their corresponding adult phase I trials were reviewed. Dose escalation schemes using fixed 30% dose increments were studied to theoretically determine whether trials could be completed utilizing fewer patients and dose levels.

RESULTS: Sixty-nine pediatric phase I oncology trials enrolling 1,973 patients were identified. The pediatric maximum-tolerated dose (MTD) was strongly correlated with the adult MTD (r = 0.97). For three-fourths of the trials, the pediatric and adult MTD differed by no more than 30%, and for more than 85% of the trials, the pediatric MTD was less than or equal to 1.6 times the adult MTD. The median number of dose levels studied was four (range, two to 13). The overall objective response rate was 9.6%, the likelihood of experiencing a dose-limiting toxicity was 24%, and toxic death rate was 0.5%.

CONCLUSION: Despite the strong correlation between the adult and pediatric MTDs, more than four dose levels were studied in 40% of trials. There appeared to be little value in exploring dose levels greater than 1.6 times the adult MTD. Limiting pediatric phase I trials to a maximum of four doses levels would significantly shorten the timeline for study conduct without compromising safety.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Kim, E. Fox, K. Warren, S. M. Blaney, S. L. Berg, P. C. Adamson, M. Libucha, E. Byrley, F. M. Balis, and B. C. Widemann Characteristics and Outcome of Pediatric Patients Enrolled in Phase I Oncology Trials Oncologist, June 1, 2008; 13(6): 679 - 689. [Abstract] [Full Text] [PDF]

				C. Hartford, S. L. Volchenboum, and S. L. Cohn 3 + 3 != (Rolling) 6 J. Clin. Oncol., January 10, 2008; 26(2): 170 - 171. [Full Text] [PDF]

				J. M. Skolnik, J. S. Barrett, B. Jayaraman, D. Patel, and P. C. Adamson Shortening the Timeline of Pediatric Phase I Trials: The Rolling Six Design J. Clin. Oncol., January 10, 2008; 26(2): 190 - 195. [Abstract] [Full Text] [PDF]